Project Grant R01DA057317

Award Date 7/1/24
Completion Date 5/31/29
Dollars Obligated $286K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
University, MS 38677, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the impact of prenatal exposure to cannabis on childhood adiposity and cardiometabolic health outcomes. The $234,000 award, with a performance period from August 2024 to July 2026, will support a study using a well-characterized observational cohort in Colorado to measure the levels of delta-9-tetrahydrocannabinol (D9-THC) and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding a $621,186 longitudinal study to examine the impact of circulating endocannabinoid levels on neurocognition, impulsivity, and early cannabis use patterns in youth enrolled in the Adolescent Brain Cognitive Development (ABCD) study. The 5-year study, running from July 2025 to March 2030, will be conducted by the University of...
This Project Grant award of $169,580 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a novel animal model study to investigate the effects of delta-9-tetrahydrocannabinol (THC) exposure during brain development in ferrets. The study aims to use RNA sequencing, electrophysiology, and in vivo electrophysiology techniques to examine changes in cannabinoid type-1 receptor (CB1R) expression and function, as well as ocular...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $716,455 to the University of Washington to conduct research on the impact of oral THC consumption during adolescence on adult mouse brain development and behavior. The key objectives of this 5-year research project are to: 1) Determine how long-term adolescent use of THC-gelatin alone or in combination with CBD impacts cannabimimetic responses and natural...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $149,000.00 to the University of Oregon to conduct a longitudinal study examining the effects of prenatal cannabis and tobacco co-exposure, as well as postnatal adversity, on child regulation and the potential buffering role of sensitive parenting. The research will assess changes in parasympathetic nervous system functioning from infancy...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study on the prevalence and effects of cannabidiol (CBD) use during pregnancy. The $188,482 award, effective February 1, 2025 through January 31, 2030, will be used by the University of Colorado-Denver to: Estimate the prevalence of CBD use among pregnant women receiving prenatal care, including by trimester. Characterize the...
This Project Grant award of $443,263 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to characterize the unique effects of recreational cannabis use on sleep in women of childbearing age. The 5-year study, beginning September 2024, will examine the relationship between cannabis use and sleep, investigating the mediating role of stress physiology and reproductive hormones. The research will utilize a within-subject design...
This $196,236 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the mechanisms contributing to preconceptions about individuals who use cannabis, especially during pregnancy. The central hypothesis is that these preconceptions result in negative interactions between patients and clinicians, reducing the quality of healthcare and leading to poor outcomes. The research aims to:...
This $2,118,992 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a longitudinal study investigating the neural and psychiatric consequences of cannabis use in depressed adolescents. The research aims to prospectively examine the effects of cannabis, the most widely used illicit drug among teenagers, on reward and pain neurocircuits in adolescents with depression. The study will evaluate 250...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...

VULNERABILITY AND PERSISTENCE OF NEUROINFLAMMATION AND BEHAVIORAL DEFICITS FROM DEVELOPMENTAL CANNABINOID EXPOSURE - ABSTRACT THIS PROPOSAL WILL ADDRESS THE CRITICAL NEED TO DEFINE FOR CANNABINOID EXPOSURE: 1) THE MOST SENSITIVE DEVELOPMENTAL EXPOSURE WINDOWS; 2) THE DOSE- AND SEX-DEPENDENCE OF ADVERSE OUTCOMES; 3) DEVELOPMENTALLY RELEVANT MOLECULAR MECHANISMS OF PERSISTENT ADVERSE EFFECTS; AND 4) THE RELATIVE DEVELOPMENTAL TOXICITY OF OTHER CANNABINOIDS AVAILABLE TO CONSUMERS. CANNABIS/9-TETRAHYDRO- CANNABINOL (THC) IS THE MOST COMMONLY USED ILLICIT DRUG BY PREGNANT WOMEN, AND CANNABIDIOL (CBD) IS READILY AVAILABLE OVER THE COUNTER WITH SUGGESTED BENEFITS IN PREGNANCY FOR MORNING SICKNESS, STRESS, AND SLEEPLESSNESS. SIMILARLY, OTHER MINOR CANNABINOIDS ARE MARKETED DIRECTLY TO CONSUMERS WITH NUMEROUS HEALTH CLAIMS. BECAUSE OF MATERNAL USE, PRE- AND POST-NATAL CANNABINOID EXPOSURES OCCUR DURING CRITICAL STAGES OF CHILDREN'S BRAIN DEVELOPMENT DESPITE OUR LACK OF UNDERSTANDING OF THE ACUTE AND LONG-TERM CONSEQUENCES. IN ADDITION, CANNABINOID EXPOSURE (E.G. VIA VAPING) FREQUENTLY OCCURS DURING ADOLESCENCE, ANOTHER SENSITIVE TIME OF BRAIN DEVELOPMENT AND NEURONAL PRUNING. IN OUR ZEBRAFISH MODEL SYSTEM, WE HAVE OBSERVED PERSISTENTLY ALTERED ADULT BEHAVIOR AFTER EMBRYOS WERE EXPOSED TO THC AND CBD DURING EARLY DEVELOPMENT. OUR CENTRAL HYPOTHESIS IS THAT EXPOSURE TO CANNABINOIDS CAUSES ALTERATIONS IN INFLAMMATORY MEDIATORS IN THE DEVELOPING BRAIN LEADING TO THE PERSISTENT ALTERATIONS IN BEHAVIOR THROUGHOUT DEVELOPMENT AND INTO ADULTHOOD. OUR RESEARCH FRAMEWORK, DEPICTED AS AN ADVERSE OUTCOME PATHWAY (AOP), WILL SPECIFICALLY INVESTIGATE THREE AIMS TO MEASURE: 1) MORPHOLOGICAL AND PERSISTENT BEHAVIORAL ALTERATIONS IN ANXIETY/LOCOMOTION; 2) TIME-OF-EXPOSURE SUSCEPTIBILITIES; AND 3) NEUROINFLAMMATION RESULTING FROM THC AND CBD DEVELOPMENTAL EXPOSURE. WE WILL USE THE HIGHLY RELEVANT, PREDICTIVE, AND HIGH THROUGHPUT ZEBRAFISH MODEL, INCLUDING THREE TRANSGENIC LINES, TO ASSESS THE SPATIAL AND TEMPORAL RELATIONSHIPS BETWEEN MICROGLIAL RESPONSE, GENE EXPRESSION, AND PERSISTENT BEHAVIORAL ADVERSE OUTCOMES. CANNABINOID-MEDIATED CHANGES IN NEUROINFLAMMATION GENE/PROTEIN EXPRESSION AND ALTERED CELLULAR TRAJECTORIES WILL BE IDENTIFIED USING SINGLE NUCLEIRNASEQ AND LC-MS/MS PROTEIN VALIDATION IN LARVAL AND ADULT BRAINS. THE DEPENDENCE OF THE SPECIFIC CANNABINOID RECEPTORS IN OBSERVED TOXICITIES WILL BE DETERMINED BY USING CANNABINOID RECEPTOR 1 AND 2 NULL LINES. OUR ONGOING AND PRODUCTIVE COLLABORATIONS, INCLUDING WORK WITH THREE NIH-COBRE CORE FACILITIES, WILL BE LEVERAGED TO INFORM THE DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE CAUSED BY CANNABINOID EXPOSURE. THE PROPOSED RESEARCH IS SIGNIFICANT BECAUSE IT WILL PROVIDE NEW, RELEVANT INFORMATION TO GUIDE CANNABINOID POLICY AND HEALTHCARE DECISIONS MADE BY PEDIATRICIANS, OBSTETRICIANS, AND POLICY- MAKERS NEEDED TO ENSURE PUBLIC HEALTH AND SAFETY.

Posted 6/19/24